Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Endoscopic Ultrasound
100%
Endoscopic Retrograde Cholangiopancreatography
82%
Neoplasm
71%
Biliary Tract Drainage
70%
Cholestasis
70%
Fine-Needle Aspiration
51%
Metastatic Carcinoma
51%
Endoscopic Ultrasound Guided Fine Needle Biopsy
50%
Pancreatitis
48%
Intraductal Papillary Mucinous Tumor
46%
Cystic Pancreatic Lesion
43%
In-Stent Restenosis
35%
Hepatocellular Carcinoma
33%
Gemcitabine
33%
Radiofrequency Ablation
32%
Cholecystectomy
28%
Cannulation
28%
Pancreatic Cysts
28%
Bile Duct
28%
Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
27%
Liver Cirrhosis
26%
Polyp
26%
Anal Sphincterotomy
26%
Biopsy Technique
24%
Health Care Cost
23%
Computer Assisted Tomography
23%
Recurrent Disease
22%
Cyst Fluid
21%
Primary Tumor
21%
Supportive Care
19%
Pancreas Islet Cell Tumor
19%
Common Bile Duct
19%
Common Bile Duct Stone
18%
Endoscopic Sphincterotomy
18%
Jaundice
18%
Acute Cholecystitis
17%
Tumor Marker
17%
Abdominal Mass
17%
Prognostic Factor
16%
Pancreatic Duct
16%
Carcinoembryonic Antigen
16%
Colon
16%
Ascites
16%
Overall Survival
16%
In Vitro
15%
Conservative Treatment
14%
Gastrointestinal Stromal Tumor
14%
Lithotripsy
14%
Chronic Pancreatitis
14%
Real Time Polymerase Chain Reaction
13%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreatitis
45%
Acute Cholecystitis
19%
Common Bile Duct Stone
19%
Gemcitabine
19%
Neoplasm
16%
Recurrent Disease
15%
Liver Cirrhosis
14%
Chronic Pancreatitis
14%
Polyp
13%
Placebo
13%
Biliary Tract Infection
13%
Ulinastatin
13%
Liver Cell Carcinoma
13%
Extended Spectrum Beta Lactamase
13%
Fluorouracil
13%
Cholestasis
13%
Klatskin Tumor
13%
Pentraxin
13%
Tumor Marker
13%
Hernia
13%
Ascites
13%
Jaundice
10%
Prevalence
9%
Cholangitis
8%
Recurrence Risk
7%
Intraductal Papillary Mucinous Tumor
6%
Cystic Neoplasm
6%
In-Stent Restenosis
6%
Intractable Pain
6%
Nafamstat Mesilate
6%
Randomized Clinical Trial
6%
Ceruletide
6%
Acute Pancreatitis
6%
Neurolysis
6%
Vorinostat
6%
Bortezomib
6%
Survival Rate
6%
Gabexate
5%
Overall Survival
5%